| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers C > Headlines for Calypte Biomedical Corp. > News item |
Calypte expands HIV-1 BED test to detect HIV in dried blood
By Angela McDaniels
Seattle, Dec. 21 - Calypte Biomedical Corp. said its Calypte HIV-1 BED Incidence EIA can now use dried blood spot samples to test for HIV. Initially, the device had only been evaluated for use with serum and plasma specimens.
Dried blood spot samples can be obtained from blood serum, blood plasma or whole blood, and Calypte said all three specimen types can be tested simultaneously with this new indication.
Most HIV antibody tests are designed as a screening test to determine if an individual has been exposed to HIV-1. The Calypte test is a population research tool intended to determine the number of persons in a known population that have been infected within a six-month period.
Additionally, the test may be valuable for targeting populations with a high incidence of HIV infections for interventional studies and/or vaccine trials, the company said.
"The addition of a dried blood spot indication will allow more flexibility with Calypte's HIV-1 BED Incidence EIA, as dried blood spots are easier to collect, handle and transport than serum or plasma samples," chairman and chief executive officer Roger Gale said in a company news release.
"The additional dried blood spot indication may allow the BED HIV-1 Incidence test to be used as a tool to facilitate collection of HIV-1 incidence data from difficult-to-reach populations in remote locations where traditional laboratory facilities and conveniences such as refrigeration are not available. Furthermore, this new indication should facilitate testing of archived dried specimens that could not have been previously tested."
The product is available in inventory and first sales have shipped.
Calypte is a health care company based in Lake Oswego, Ore., that develops and commercializes diagnostic testing products for the detection of sexually transmitted diseases.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.